Venclyxto

Venclyxto is a cancer medicine used to treat adults with the following blood cancers: - chronic lymphocytic leukaemia (CLL). - acute myeloid leukaemia (AML). For CLL, it is used either in combination with other cancer medicines or on its own. Venclyxto can be used with obinutuzumab in patients who have not previously been treated for CLL or with rituximab in patients who have received at least one previous treatment. Obinutuzumab and rituximab are immunotherapy medicines (medicines that act through the body’s defence system). It can also be used on its own in: - patients with particular genetic changes (17p deletion or TP53 mutation) who cannot be treated with medicines known as B‑cell receptor pathway inhibitors (ibrutinib and idelalisib) or if these medicines have stopped working. - patients who do not have these genetic changes, after treatments with chemotherapy combined with immunotherapy as well as a B‑cell receptor pathway inhibitor have both not worked. For AML, Venclyxto is used in combination with either azacitidine or decitabinein adults who cannot have intensive chemotherapy. Venclyxto contains the active substance venetoclax.